Abstract:Background: Breast cancer is a caomplex disease with high prevalence in women, the molecular mechanisms of which are still unclear at present. Most transcriptomic studies on breast cancer focus on differential expression of each gene between tumor and the adjacent normal tissues, while the other perturbations induced by breast cancer including the gene regulation variations, the changes of gene modules and the pathways, which might be critical to the diagnosis, treatment and prognosis of breast cancer are more or less ignored. Objective: We presented a complete process to study breast cancer from multiple perspectives, including differential expression analysis, constructing gene co-expression networks, modular differential connectivity analysis, differential gene connectivity analysis, gene function enrichment analysis key driver analysis. In addition, we prioritized the related anti-cancer drugs based on enrichment analysis between differential expression genes and drug perturbation signatures. Methods: The RNA expression profiles of 1109 breast cancer tissue and 113 non-tumor tissues were downloaded from The Cancer Genome Atlas (TCGA) database. Differential expression of RNAs was identified using the DESeq2 bioconductor package in R, and gene co-expression networks were constructed using the weighted gene co-expression network analysis (WGCNA). To compare the module changes and gene co-expression variations between tumor and the adjacent normal tissues, modular differential connectivity (MDC) analysis and differential gene connectivity analysis (DGCA) were performed. Results: Top differential genes like MMP11 and COL10A1 were known to be associated with breast cancer. And we found 23 modules in the tumor network had significantly different co-expression patterns. The top differential modules were enriched in Goterms related to breast cancer like MHC protein complex, leukocyte activation, regulation of defense response and so on. In addition, key genes like UBE2T driving the top differential modules were significantly correlated with the patients' survival. Finally, we predicted some potential breast cancer drugs, such as Eribulin, Taxane, Cisplatin and Oxaliplatin. Conclusion: As an indication, this framework might be useful in understanding the molecular pathogenesis of diseases like breast cancer and inferring useful drugs for personalized medication.

A Co-essentiality Network of Cancer Driver Genes Better Prioritizes Anticancer Drugs

Reducing State Conflicts between Network Motifs Synergistically Enhances Cancer Drug Effects and Overcomes Adaptive Resistance

Enhancing Cancer Driver Gene Prediction by Protein-Protein Interaction Network

A network medicine approach for identifying diagnostic and prognostic biomarkers and exploring drug repurposing in human cancer

Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis

Prediction of Potential Drivers Connecting Different Dysfunctional Levels in Lung Adenocarcinoma Via a Protein–protein Interaction Network

Cancer Network Activity Associated with Therapeutic Response and Synergism.

Prioritization of Candidate Cancer Drugs Based on a Drug Functional Similarity Network Constructed by Integrating Pathway Activities and Drug Activities

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery

Pre-Clinical Drug Prioritization Via Prognosis-Guided Genetic Interaction Networks

DrugComboRanker: Drug Combination Discovery Based on Target Network Analysis

In silico Genetic Network Models for *Pre-clinical Drug Prioritization

Accelerating Complex Disease Treatment through Network Medicine and GenAI: A Case Study on Drug Repurposing for Breast Cancer

Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations

Discovery of novel therapeutic targets in cancer using patient-specific gene regulatory networks

A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma

Drug Screening and Biomarker Gene Investigation in Cancer Therapy Through the Human Transcriptional Regulatory Network

Identifying Breast Cancer-induced Gene Perturbations and its Application in Guiding Drug Repurposing

Network-based identification of key proteins and repositioning of drugs for non-small cell lung cancer

Network controllability-based algorithm to target personalized driver genes for discovering combinatorial drugs of individual patients

Drug Repositioning in Head and Neck Squamous Cell Carcinoma: an Integrated Pathway Analysis Based on Connectivity Map and Differential Gene Expression.